Research location
Udine
UD, Italy
Advertisement
Research activity in Udine
UD, ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 33 trials and 33 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Udine
33 linked trials · page 1 of 1Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLCNCT07356544 · 2025-08-12 · 1 site observation
RECRUITING
Integrated Approach in Frail Older People with Atrial FibrillationNCT06775028 · 2024-04-11 · 1 site observation
RECRUITING
PREgnancy and FERtility RegistryNCT02895165 · 2012-11-01 · 1 site observation
RECRUITING
Selective, Micropulse and Pattern Laser Trabeculoplasty in Medically Treated Open-angle Glaucoma.NCT07756411 · 2025-02-01 · 1 site observation
COMPLETED
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisNCT06655896 · 2024-10-29 · 1 site observation
ACTIVE_NOT_RECRUITING
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS PatientsNCT06345157 · 2024-07-30 · 1 site observation
ACTIVE_NOT_RECRUITING
BRING-UP 3 Heart FailureNCT06279988 · 2023-09-15 · 1 site observation
UNKNOWN
Endocannabinoid Activity Remodulation for Psychosis Liability in YouthNCT06037993 · 2022-11-01 · 1 site observation
UNKNOWN
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeNCT05349214 · 2022-08-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's SyndromeNCT03905525 · 2019-10-01 · 1 site observation
COMPLETED
Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast CancerNCT04113863 · 2019-06-18 · 1 site observation
TERMINATED
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantNCT03439046 · 2018-02-02 · 1 site observation
TERMINATED
BLITZ Heart FailureNCT03661060 · 2017-03-08 · 1 site observation
COMPLETED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody AvelumabNCT02926196 · 2016-06-17 · 1 site observation
COMPLETED
"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "NCT02530424 · 2015-05-01 · 1 site observation
COMPLETED
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerNCT02278120 · 2014-11-20 · 1 site observation
COMPLETED
Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsNCT02511639 · 2014-07-30 · 1 site observation
COMPLETED
Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal TherapyNCT02411344 · 2014-02-01 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFNCT01870778 · 2013-10-02 · 1 site observation
COMPLETED
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerNCT01828099 · 2013-07-09 · 1 site observation
COMPLETED
Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast CancerNCT01822314 · 2013-04-01 · 1 site observation
COMPLETED
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung CancerNCT01297491 · 2011-05-01 · 1 site observation
COMPLETED
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)NCT01242514 · 2011-01-01 · 1 site observation
TERMINATED
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisNCT01201356 · 2010-09-13 · 1 site observation
COMPLETED
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.NCT01197534 · 2010-09-01 · 1 site observation
COMPLETED
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailureNCT00853658 · 2009-03-01 · 1 site observation
COMPLETED
Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus GemcitabineNCT00753714 · 2008-10-01 · 1 site observation
COMPLETED
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)NCT00549757 · 2007-10-01 · 1 site observation
TERMINATED
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast CancerNCT00248170 · 2005-12-01 · 1 site observation
COMPLETED
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate CancerNCT00233610 · 2003-12-01 · 1 site observation
COMPLETED
GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHFNCT00336336 · 2002-08-01 · 1 site observation
COMPLETED
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate CancerNCT00673205 · 1995-09-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.